52130 Federal Register / Vol. 72, No. 176 / Wednesday, September 12, 2007 / Notices 

A. Federal Reserve Bank of Cleveland 

(Douglas A. Banks, Vice President) 1455 

East Sixth Street, Cleveland, Ohio 

44101–2566: 

1. KeyCorp, and KYCA Corporation, 

both of Cleveland, Ohio; to merge with 

U.S.B. Holding Co. Inc., Orangeburg, 

New York, and thereby indirectly 

acquire Union State Bank, Nanuet, New 

York. 

In connection with this application, 

KYCA Corporation; has applied to 

become a bank holding company by 

acquiring 100 percent of the voting 

shares of Union State Bank, Nanuet, 

New York. 

Board of Governors of the Federal Reserve 

System, September 7, 2007. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc. E7–17944 Filed 9–11–07; 8:45 am] 

BILLING CODE 6210–01–S 

FEDERAL RESERVE SYSTEM 

Sunshine Act Meeting 

AGENCY HOLDING THE MEETING: Board of 

Governors of the Federal Reserve 

System. 

TIME AND DATE: 12:00 p.m., Monday, 

September 17, 2007. 

PLACE: Marriner S. Eccles Federal 

Reserve Board Building, 20th and C 

Streets, N.W., Washington, D.C. 20551. 

STATUS: Closed. 

MATTERS TO BE CONSIDERED: 

1. Personnel actions (appointments, 

promotions, assignments, 

reassignments, and salary actions) 

involving individual Federal Reserve 

System employees. 

2. Any items carried forward from a 

previously announced meeting. 

FOR FURTHER INFORMATION CONTACT: 

Michelle Smith, Director, or Dave 

Skidmore, Assistant to the Board, Office 

of Board Members at 202–452–2955. 

SUPPLEMENTARY INFORMATION: You may 

call 202–452–3206 beginning at 

approximately 5 p.m. two business days 

before the meeting for a recorded 

announcement of bank and bank 

holding company applications 

scheduled for the meeting; or you may 

contact the Board’s Web site at http:// 

www.federalreserve.gov for an electronic 

announcement that not only lists 

applications, but also indicates 

procedural and other information about 

the meeting. 

Board of Governors of the Federal Reserve 

System, September 7, 2007. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc. 07–4492 Filed 9–7–07; 5:02 pm] 

BILLING CODE 6210–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Toxicology Program (NTP) 

Interagency Center for the Evaluation 

of Alternative Toxicological Methods 

(NICEATM); Draft Performance 

Standards for the Murine Local Lymph 

Node Assay: Request for Comments 

AGENCY: National Institute of 

Environmental Health Sciences 

(NIEHS), National Institutes of Health 

(NIH). 

ACTION: Request for comments. 

SUMMARY: The Murine Local Lymph 

Node Assay (LLNA) is the first 

alternative test method evaluated and 

recommended by the Interagency 

Coordinating Committee on the 

Validation of Alternative Methods 

(ICCVAM). It was subsequently 

accepted by regulatory authorities to 

determine the allergic contact dermatitis 

potential of chemicals and products. In 

January 2007, the U.S. Consumer 

Product Safety Commission (CSPC) 

submitted a nomination requesting that 

NICEATM and ICCVAM assess the 

validation status of (1) The LLNA as a 

stand-alone assay for potency 

determination for hazard classification 

purposes; (2) modified LLNA protocols; 

(3) the LLNA limit test; (4) the use of 

LLNA to test mixtures, aqueous 

solutions, and metals; and (5) the 

applicability domain for LLNA. In order 

to facilitate the review of the modified 

LLNA protocols, ICCVAM proposed 

developing performance standards for 

the LLNA. In May 2007, a Federal 

Register notice was published (Vol. 72, 

No. 95, pages 27815–27817, May 17, 

2007) requesting comments and data 

relevant to these nominated activities. 

In June 2007, the Scientific Advisory 

Committee on Alternative Toxicological 

Methods (SACATM) endorsed the 

nominated activities as high priorities 

for ICCVAM. In response to SACATM 

comments, along with those provided 

by the public in response to the 

previous Federal Register notice, 

ICCVAM also endorsed these activities 

as high priorities. ICCVAM 

subsequently prepared draft 

performance standards for the LLNA 

and now requests public comments on 

this draft document, which is available 

on the NICEATM/ICCVAM Web site at: 

(http://iccvam.niehs.nih.gov/methods/ 

immunotox/immunotox.htm) or by 

contacting NICEATM (see FOR FURTHER

INFORMATION CONTACT below). 

DATES: Submit comments on or before 

October 29, 2007. 

ADDRESSES: Dr. William S. Stokes, 

NICEATM Director, NIEHS, P.O. Box 

12233, MD EC–17, Research Triangle 

Park, NC 27709, (fax) 919–541–0947, (email) 

niceatm@niehs.nih.gov. Courier address: 

NICEATM, 79 T.W. Alexander Drive, 

Building 4401, Room 3128, Research 

Triangle Park, NC 27709. Responses can 

be submitted electronically at the 

ICCVAM–NICEATM Web site: http:// 

iccvam.niehs.nih.gov/contact/ 

FR_pubcomment.htm or by e-mail, mail, 

or fax. 

FOR FURTHER INFORMATION CONTACT: 

Other correspondence should be 

directed to Dr. William S. Stokes (919–

541–2384 or niceatm@niehs.nih.gov). 

SUPPLEMENTARY INFORMATION: 

Background 

The LLNA is an alternative test 

method used for skin sensitization 

testing that reduces the number of 

animals needed, reduces the time 

required for testing, and can 

substantially reduce or avoid pain and 

distress associated with traditional 

guinea pig testing methods. The LLNA 

was the first alternative test method 

evaluated and recommended by 

ICCVAM and based on the 

recommendations of ICCVAM and an 

independent scientific peer review 

panel, the LLNA has been accepted by 

U.S. and international regulatory 

authorities as an alternative to the 

guinea pig maximization test and 

Buehler test for assessing allergic 

contact dermatitis (EPA 2003; ISO 2002; 

OECD 2002). Since 2003, ICCVAM has 

routinely developed performance 

standards for test methods; however, 

because the concept of performance 

standards was not developed by 

ICCVAM until 2003, they were not 

developed during the ICCVAM 

evaluation of the LLNA in 1998 (NIH 

Publication No. 99–4494, available: 

(http://iccvam.niehs.nih.gov/docs/ 

immunotox_docs/llna/llnarep.pdf). 

In January 2007, CSPC submitted a 

nomination requesting that NICEATM 

and ICCVAM assess the validation 

status of (1) The LLNA as a stand-alone 

assay for potency determination for 

classification purposes; (2) modified 

LLNA protocols; (3) the LLNA limit test; 

(4) the use of LLNA to test mixtures, 

aqueous solutions, and metals; and (5) 

the applicability domain for LLNA. 

ICCVAM endorsed the nomination and 

also decided to develop performance 

standards to facilitate evaluation of 

modified LLNA protocols to the 

traditional LLNA. In May 2007, a 

Federal Register notice was published 

requesting comments and data relevant 

to these activities (Vol. 72, No. 95, pages 

27815–27817, May 17, 2007; available, 


jlentini on PROD1PC65 with NOTICES